Growth Response of Acute Myeloid Leukemic Blasts to GM-CSF In Vitro and In Vivo — Observations in One Patient

  • W. Hiddemann
  • M. Zühlsdorf
  • B. Wörmann
  • M. Koenigsmann
  • T. Büchner
Conference paper

Abstract

Treatment-induced granulocytopenia is a major dose-limiting factor for cytostatic therapy, in general, and is of high relevance in patients with acute leukemias in particular, due to the additional suppression of normal hematopoietic cells by the underlying disease. Hence, neutropenia-associated infections are the predominant cause of treatment failure, especially in elderly patients with acute myeloid leukemia (AML) undergoing intensive cytostatic therapy [1–3].

Keywords

Leukemia Oncol Neutropenia Cytosine Adriamycin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rai DR, Holland JF, Glidewell OJ, Weinberg V, Brunner K, Obrecht UP, Preisler HD, Nawabi IW, Prager D, Carey RW, Cooper MR, Haurani F, Hutchison JL, Silver RT, Falkson G, Wiernik P, Hoagland HC, Bloomfield CD, James GW, Gottlieb A, Ramanan SV, Blom J, Nissen NI, Bank A, Ellison RR, Kung F, Henry P, McIntryre OR, Kaan SK (1981) Treatment of acute myelocytic leukemia:a study by Cancer and Leukemia Group B. Blood 58:1203–1212PubMedGoogle Scholar
  2. 2.
    Yates H, Glidewell O, Wiernik P, Cooper MR, Steinberg D, Dosik H, Levy R, Hoagland C, Henry P, Gottlieb A, Cornell C, Berenberg J, Hutchinson JL, Raich P, Nissen N, Ellison RR, Frelick R, James GW, Falkson G, Silver RT, Haurani F, Green M, Henderson E, Leone L, Holland JF (1982) Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia:a CALGB study. Blood 60:454–462PubMedGoogle Scholar
  3. 3.
    Preisler H, Davis RB, Kirshner J, Dupre E, Richards F III, Hoagland HC, Kopel S, Levy RN, Carey R, Schulman P, Gottlieb AJ, McIntyre OR, Cancer and Leukemia Group B (1987) Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia:a Cancer and Leukemia Group B study. Blood 69:1441–1449PubMedGoogle Scholar
  4. 4.
    Bronchud MH, Scarffe JH, Thatcher N, Crowther D, Souza LM, Alton NK, Testa NG, Dezter TM (1987) Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 56:809–813PubMedCrossRefGoogle Scholar
  5. 5.
    Gabrilove JL, Yakubowski A, Scher H, Sternberg C, Wong G, Grous J, Yagoda A, Fain K, Moore MAS, Clarkson B, Oettgen HF, Alton K, Welte K, Souza L (1988) Effects of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transtional-cell carcinoma of the urothelium. N Engl J Med 318:1414–1422PubMedCrossRefGoogle Scholar
  6. 6.
    Antman KS, Griffin JD, Elias A, Socinski MA, Ryan L, Cannistra SA, Oette D, Whitely M, Frei E III, Schnipper LE (1988) Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Eng J Med 319:593–598CrossRefGoogle Scholar
  7. 7.
    Brandt SJ, Peters WP, Atwater SK, Kurtzberg J, Borowith MJ, Jones RJ, Shpall EJ, Bast RC, Gilbert CJ, Oette D (1988) Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 318:869–876PubMedCrossRefGoogle Scholar
  8. 8.
    Herrmann F, Schulz G, Lindemann A, Meyenburg W, Oster W, Krumwieh D, Mertelsmann R (1989) Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor. J Clin Oncol 7:159–169PubMedGoogle Scholar
  9. 9.
    Vellenga E, Young DC, Wagner K, Wiper D, Ostapovicz D, Griffin JD (1987) The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblasts leukemia. Blood 69:1771–1776PubMedGoogle Scholar
  10. 10.
    Asano Y, Shibuya T, Okamura S, Yamaga S, Otsuka T, Niho Y (1987) Effect of human recombinant granuloctye/macrophage colony-stimulating factor and native granulocyte colony-stimulating factor on clonogemic leukemic blast cells. Cancer 47:5647–5648Google Scholar
  11. 11.
    Cannistra SA, Groshek P, Griffin JD (1989) Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblasts leukemia and in the myeloid blast crisis phase of chronic meyloid leukemia. Leukemia 3:328–334PubMedGoogle Scholar
  12. 12.
    Andreeff M, Tafuri A, Hegewisch-Becker S (1990) Colony stimulating factors (rhG-CSF, rhGM-CSF, rhIL-3, and BCFG) recruit myeloblasts and lymphoblastic leukemic cells and enhance the cytotoxic effects of cytosine arabinoside. In:Büchner T, Schellong G, Hiddemann W, Ritter J (eds) Acute leukemias:prognostic factors and treatment strategies II. Springer, Berlin Heidelberg New York (in press)Google Scholar
  13. 13.
    Büchner T, Hiddemann W, Koenigsmann M, Zühlsdorf M, Wörmann B, Boeckmann A, van de Loo J, Maschmeyer G, Wendt F, Schulz G (1988) Human recombinant granulocyte macrophage colony stimulating factor (GM-CSF) for acute leukemias in aplasia and at high risk of early death. Blood 72:111 (abstr)Google Scholar
  14. 14.
    Büchner T, Hiddemann W, Koenigsmann M, Zühlsdorf M, Wörmann B, Boeckmann A, Maschmeyer G, Ludwig W, Schulz G (1989) Chemotherapy (CT) followed by recombinant human granulocyte macrophage colony stimulating factor (GM-CSF) for acute leukemias at higher age or after relapse. Proc Am Soc Clin Oncol 8:198 (abstr)Google Scholar
  15. 15.
    Büchner T, Hiddemann W, Blasius S. Koch P, Maschmeyer G, Tirier C, Sodomann H, Kuse R, Thiel E, Ludwig WD, Seibt-Jung H, Gassmann W, Löffler H, Aul C, Heyll A, Mertelsmann R, Anders CH, Nowrousian MR, Straif K, Hossfeld D, Becker K, Ho A, Fülle HH, Hellriegel K-P, Konig HJ, Lengfelder E, Siegert W, Bartels H, Schwammborn J, Donhuijsen-Ant R, Vaupel HA, König E, Planker M, Emmerich R, Middelhoff G, Mainzer K, Urbanitz D, Zurborn K-H, Köppler H, Nowicki L, Augener W, Karow J, Schroeder M, Eimermacher H, Fuchs R, Balleisen L, Schmitz-Huebner U, Leimer L, Heitzelmann KH, Lathan B, Meuthen I, Baldus M, Michels-Giermann R, Fuhr HG, Sauerland MC, Heinecke A (1990) Adult AML:the role of chemotherapy intensity and duration. Two studies of the AMLCG. In:Büchner T, Schellong G, Hiddemann W, Ritter J (eds) Acute leukemias:prognostic factors and treatment strategies II. Springer, Berlin Heidelberg New York (in press)Google Scholar
  16. 16.
    Hiddemann W, Schumann J, Andreeff M, Barlogie B, Herman CJ, Leif RC, Mayall BH, Murphy RF (1984) Convention on nomenclature for DNA cytometry. Cancer Genet Cytogenet 13:181–183PubMedCrossRefGoogle Scholar
  17. 17.
    Hiddemann W, Wörmann B, Göhde W, Büchner T (1986) DNA aneuploidies in adult patients with acute myeloid leukemia:incidence and relation to patient characteristics and morphologic subtypes. Cancer 57:2146–2152PubMedCrossRefGoogle Scholar
  18. 18.
    Krehmeier C, Zühlsdorf M, Hiddemann W (1990) Synergistic cytotoxicity of cytosine arabinoside and mitoxantrone for K562 and CFU-GM. In:Büchner T, Schellong G, Hiddemann W, Ritter J (eds) Acute leukemias:prognostic factors and treatment strategies II. Springer, Berlin Heidelberg New York (in press)Google Scholar
  19. 19.
    Ganser A, Volkers B, Greher J, Ottmann OG, Walther F, Becher R, Bergmann L, Schulz G, Hoelzer D (1989) Recombinant human granuloctye-macrophage colony-stimulating factor in patients with myelodysplastic syndromes — a phase I/II trial. Blood 73:31–37PubMedGoogle Scholar

Copyright information

© Springer-Verlag, Berlin Heidelberg 1990

Authors and Affiliations

  • W. Hiddemann
  • M. Zühlsdorf
  • B. Wörmann
  • M. Koenigsmann
  • T. Büchner

There are no affiliations available

Personalised recommendations